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Abstract:  Familial Mediterranean Fever (FMF) is an autoinflammatory periodic disorder. We aim to identify the 
distribution and the frequency of the Mediterranean Fever (MEFV) gene mutations in the east of Anatolia in Turkey and 
perform a genotype/phenotype correlation in the patients’ cohort. The study was carried out on 415 clinically diagnosed 
Turkish FMF patients and 103 healthy controls. The tested individuals were screened for the most common twelve MEFV 
mutations. The most important features were the predominance of the M694V and E148Q mutations in patient group and 
the earlier of onset of the disease in M694V mutation carriers compared with the carriers of other mutations (P=0.00). We 
discuss the high frequency of E148Q mutations in patient group compared with controls, genetic counseling in 
intermarriage families and the variations in mutation frequency according to regions of Turkey. 
Keywords: Familial mediterranean fever, mutation screening, genetic counseling, M694V mutation. 
INTRODUCTION 
  Despite its striking symptom pattern, Familial 
Mediterranean Fever (FMF; MIM# 249100), was first 
described as a distinct entity in 1945 [1]. FMF, the most 
frequent hereditary recurrent fever, is an autosomal recessive 
disease that affects commonly populations of Armenian, 
Arab, Sephardic Jewish or Turkish origin and it is not 
uncommon in other Mediterranean populations, such as 
Italians, Spanish, Portuguese, French, and Greeks [2, 3]. The 
historic trace-back of the shared haplotype and common 
mutations suggests a common ancestor at least 2000 years 
ago, when most of these populations were living together in 
the eastern Mediterranean basin, around Mesopotamia [3-6]. 
The carrier frequency of MEFV mutations is quite high in 
the 4 classically affected populations, ranging from 37-39% 
in Armenians and Iraqi Jews to 20% in Turks, North African 
and Ashkenazi Jews, and Arabs [1]. 
  Although an unexplained clinical heterogeneity is not 
uncommon, the diagnosis of the disease, which is based on 
various sets of clinical criteria [2, 7], can be confirmed by 
molecular means that provides the only objective diagnostic 
criterion in the absence of functional test. In 1997 the gene 
linked to FMF, called MEFV, was cloned from to 
chromosome 16p using positional cloning and some of the 
mutations associated with the disease were identified [1, 6]. 
The gene comprises 10 exons, spanning approximately 15 kb 
of genomic DNA and encodes a 781 amino acid-long 
protein. All four of the initial FMF-associated mutations in 
MEFV were in exon 10, and even now, with over 55 
mutations having been identified (see the Infevers database 
of FMF and hereditary autoinflammatory disorders 
mutations online at http://fmf.igh.cnrs.fr/infevers), exon 10  
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remains the major site of mutations, with a smaller cluster in 
exon 2 [2, 5, 6]. Nearly all of the known FMF-associated 
mutations encode conservative missense changes [8-10]. The 
most frequent mutations (M 680 I, M 694 V, V726 A, M 694 
I and E 148 Q) are found in more than two thirds of cases 
[10, 11]. 
  The protein encoded by the MEFV gene, termed pyrin or 
marenostrin, includes a PYRIN domain (PYD), which has 
been already analyzed crystallographically [12]. Pyrin 
presumably participates in a complex interplay with the PYD 
protein superfamily, lipopolysaccharide (LPS) via Toll-like 
receptor family and procaspase-1 activation, and is 
implicated in the homeostatic control of inflammation 
through leukocyte apoptosis, IL-1, and NF-B pathway 
activation [13-15]. However, the precise function of the 
entire pyrin protein is still unknown [1, 5, 6].  
  Molecular analysis of MEFV is a useful tool in clinical 
practice, mainly in the atypical forms of the disease [16]. 
However, many clinically typical FMF patients are 
heterozygous or no disease-associated mutations are found 
[16-18]. The incomplete penetrance and the varying 
expression of FMF suggest the presence of other, possibly 
genetic, factors that could influence the expression of illness 
[4, 19]. Colchicine is the preferred drug for FMF [17]. 
Genotype-phenotype correlation, thoroughly studied over the 
past few years, suggested that mutations located within the 
mutational hotspots in codons 680 and 694 are associated 
with severe disease, early onset, high frequency of attacks, 
the necessity of a high dose of colchicine to control attacks, 
and frequent occurrence of amyloidosis in untreated patients 
[20]. 
  The present study aim to investigate the twelve most 
common MEFV mutations frequency in the east of Anatolia 
in Turkey and to compared these results with the studies 
performed in other regions of Turkey, in order to provide a 
link which will facilitate the clinical interpretation of 
individualized genetic data and to evaluate the phenotypic 2   The Open Rheumatology Journal, 2010, Volume 4  Ebru Etem 
features of Turkish FMF patients with the E148Q mutation 
in homozygous, heterozygous, and complex states in order to 
shed light on the clinical presentation of this mutation 
compared with healthy subjects. 
MATERIALS AND METHODOLOGY 
Study Design and Patients 
  The study was approved by the Human Studies Ethics 
Committee of Firat University Hospital in the east of 
Anatolia region of Turkey. Clinical data on these patients 
were obtained from the records of Firat University Hospital. 
All patients were obtained at the Pediatric Clinic and 
Rheumatology Clinic of Firat University Hospital and a 
number of medical centers in the east of Anatolia region on 
Turkey. Diagnosis of FMF patients was established 
according to previously described criteria [11]. All of them 
were interviewed directly by one of clinicians with identical 
clinical forms. These included patients meeting clinical 
criteria for FMF who desired genetic confirmation of the 
diagnosis; individuals with unexplained fever, abdominal 
pain, or arthritis atypical of FMF who were seeking a 
diagnosis; and several asymptomatic relatives of patients. 
The diagnosis of FMF was based on a typical clinical picture 
of recurrent attacks of fever and pain affecting patients, and 
involving one or two of the following sites at a time: 
abdomen, chest, joints, muscles, scrotum, and skin. In 
addition, an increase in acute phase reactants during the 
attacks, a positive history among siblings or in the extended 
family, and a good response to colchicine helped to establish 
the diagnosis. We viewed the records of all patients and 
looked at the following details: family origin; age of onset; 
clinical features (fever, abdominal, thoracic, articular, skin, 
muscular, testicular, and miscellaneous manifestations); 
severity of the disease by number of attacks per month and 
duration of attack. The study group included 1100 patients, 
who were clinically suspected as FMF and 103 healthy 
controls. 
Genetic Testing 
  2 ml blood samples were collected from all subjects. 
Genomic DNA was extracted from whole blood by means of 
the Promega Wizard
® Genomic DNA Purification Kit 
(Promega, USA). Twelve common MEFV gene mutations 
located in exon 2 (E148Q), exon 3 (P369S), exon 5 (F479L), 
and exon 10 [M680I (G/C), M680I (G/A), I692del, M694V, 
M694I, K695R, V726A, A744S, and R761H] were studied 
with a reverse hybridization assay as described by the 
manufacturer (FMF Strip Assay; Vienna Lab 
Labordiagnostika GmbH, Vienna, Austria) [21]. 
  103 unrelated population-matched healthy controls were 
enrolled in the study for detection M694V, V726A, M680I, 
E148Q, M694I, P369S, A744S and R761H mutation rate. 
Mutation identification in healtly controls was performed 
according to previously described techniques. The mutations 
were assessed by amplifying the genomic DNA template 
with amplification refractory mutation system (ARMS) or 
restriction fragment length polymorphism (RFLP) [1, 22]. 
Genetic Counseling 
 Genetic counseling was
 given by counselors who have, 
besides their training
 in genetics, substantial experience in an 
FMF clinic. We aim to identify couples
 who are at risk of 
giving birth to children affected with FMF disease. 
Statistical Analysis 
  Data were analyzed using the SPSS program (SPSS Inc, 
Chicago, IL, USA). Comparisons among groups of patients 
with different combination of mutations in diagnosed FMF 
patients clinically and mutation anlysis were done by 
analysis of variance. Categorical variables were compared by 
using the x
2 test. Differences between the proportion of 
patients with diagnosed FMF and the proportion with 
ethnicaly mathod healthy control populations were compared 
statisticaly by the two tailed Fisher’s exact test. 
RESULTS 
  The analysis of clinical features showed classical 
patterns. The majority of the patients had fever and 
abdominal pain during attacks, less frequently thoracic pain 
and arthritis and rarely amyloidosis. Table 1 summarizes 
clinical symptoms of 415 patients. The majority of patients 
experienced an increase of the frequency and intensity of 
attacks following a stressing event (324/430, 75.3%). 
Table 1.  Phenotypic Features of 415 FMF Patients 
 
N = 415  Frequency (%) 
Male/Female  251/179 
Age at onset (yr±SD)  13.9±9.8 
Abdominal pain  386 (93.0%) 
Fever  379 (91.3%) 
Arthritis   242 (58.3%) 
Chest pain  17 (4.0%) 
Erysipelas-like erythema  9 (2.1%) 
Family history of FMF  238 (57.3%) 
Family history of amyloidosis  3 (0.7%) 
 
  415 of 1100 patients suspected as FMF were diagnosed 
as having FMF according to Yalcınkaya et al. [11]. Of these 
415 patients, 251 were males and 179 were females; 268 
were adult patients and 162 were children. 64 (23.8%) adults 
patients were married to their relatives and the parents of 
21(12.9%) children patients were relative. 
  Among the 586 of 1100 patients, 10.2% (60/586) were 
homozygotes, 30.8% (181/586) compound heterozygotes 
and 58.8% (345/586) heterozygotes. No mutation was found 
in the remaining 514 of FMF patients. It was not found the 
clinical findings in 51.5% (178/345) of heterozygotes 
mutation carrier patients. Seven of 415 clinically FMF 
patients did not found any mutation. But, we detected 
clinical features in addition to high fibrinogen and CRP 
levels in patients serum during attacks in seven patients with 
negative mutation analysis result. These patients were only 
the carrier for MEFV gene mutation without clinical 
symptoms. The detected mutations were mainly M694V, 
V726A, M680I and E148Q. The only rare ones were K695R, 
M694I and F479L. The distribution of FMF mutations in the 
study groups is given in Table 2. Table 3 showed the Familial Mediterranean Fever  The Open Rheumatology Journal, 2010, Volume 4   3 
mutation results of 415 patients with one and more mutations 
for determine the general mutation profile in the east of 
Anatolia. The most common mutation in patients group was 
M694V, followed by E148Q, V726A and M680I. We did not 
detect a I692del mutation in patient group. A familial history 
of the disease was noticed in 56.3% of the patients and the 
females/males ratio was estimated to 1.4 (251/179). 
Table 3.  Mutation Profiles of 415 Patients with FMF 
 
Alleles (830)  Number/Frequencies 
M694V 180  (21.6%) 
E148Q 159  (19.1%) 
V726A  81 (9.7% ) 
M680I  79 (9.5% ) 
P369S 31  (3,7%) 
R761H 17  (2.0%) 
A744S 11  (1.3%) 
K695R 8  (0,9%) 
M694I 8  (0,9%) 
F479L 1  (0,1%) 
Other/undefined mutation  255 (30.7%) 
 
  We assessed the relations between all mutations and 
clinical characteristic in 415 FMF patients. The mean age of 
onset of the disease was the lower in M694V mutation 
carrier (9.3 years) compared with other mutations carriers 
(13.2 years) (P = 0.00) by Mann-Whitney U test. However, It 
was not detected any association between other clinical 
characteristics and the specific mutations. 
  In the healthy controls group, mutation analysis showed 
that 24 (23.3%) of the subjects were carrying at least one 
mutated MEFV allele. The frequencies of E148Q, M694V, 
M694I, V726A and P369S mutation carriage were 12.6% 
(with 13/206 allele frequency), 5.8% (6/206), 1.9% (2/206), 
1.9% (2/206) and 0.9% (1/206), respectively. The 
distribution of the eight most common mutations among 
healthy individulas was significantly different from that 
found in patients. The overall allele frequency calculated 
from the mutation frequencies in the healthy controls was 
12% for E148Q. Compared with healthy controls (12%), 
FMF patients (19.1%) showed high E148Q allele frequencies 
by fisher’s exact test (p = 0.001). 
  E148Q mutation was detected in 159 patients, 37 patients 
were compound heterozygous and 123 patients were 
heterozygous. It was clinically diagnosed FMF in 25 of 37 
compound heterozygous for E148Q mutation, eighteen were 
carrying E148Q/M694V, three were carrying E148Q/P369S, 
one was carrying E148Q/V726A, one was carrying 
E148Q/M680I, E148Q/K695R, and one was carrying 
E148Q/M680I. One was carrying E148Q/P369S/A744S of 
123 heterozygotes patients for E148Q carrier. 
  Genetic counseling was given all patients with 
homozygous, heterozygous, complex states or negative 
result. We advice to get genetic test done the siblings of 
patients with homozygous, compound homozygous, 
heterozygous mutation carrier and clinically diagnosed FMF 
and thirty two patients with second and third degree or more 
distant relatives to make marriage. 
DISCUSSION 
  In the present study, we report the frequencies of the 
twelve most common MEFV mutations among Turkish FMF 
patients in the east of Anatolia region and the phenotype/ 
genotype correlations in those FMF patients. This is the first 
study reporting MEFV gene mutation profile in the east of 
Anatolia and significant evidence for the undefined muta-
tions in patients with E148Q mutation carrier. Our results are 
in agreement with the most frequent four mutations from the 
other study groups from Turkey [10, 11, 21-30]. 
  In the studies by Touitou et al. [4], and by the Turkish 
FMF study group [31], the most common MEFV mutation in 
Table 2.  Distributions of Alleles in Studies of Different Groups from Turkey 
 
Author n  No FMF 
Patients 
Allele 
Number 
M694V V726A M680I  E148Q  Other/Undefinied 
Mutation 
Akin et al. [23]  1,201  654 (54.5%)  2,402 375  (15.6%)  102 (4.2%)  94 (3.9%)  132 (5.5%)  391 (16.3%) 
Ozturk et al. [24]  201  83 (41.3%)  402  210 (52.2%)  6 (1.5%)  6 (1.5%)  14 (3.5%)  0 (0%) 
Solak et al. [25]  202  0 (0%)  404  146 (36.1%)  37 (9.2%)  48 (11.9%)  56 (13.9%)  117 (29.0%) 
Sahin et al. [26]  263 111  (42.2%)  526 109  (20.7%)  37 (7.0%)  19 (3.6%)  35 (6.7%)  104 (19.8%) 
Pasa et al. [27]  119  -  238  65(27.3%)  50 (8.4%)  10 (4.2%)  50 (21.0%)  - 
Yigit et al. [28]  625 151  (24.2%)  1,250 421  (33.7%)  62 (5.0%)  194(15.5%)  42 (3.4%)  229 (18.3%) 
Yilmaz et al. [10]  450 104  (23.1%)  900 464  (51.6%)  28 (3.1%)  84 (9.3%)  29 (3.2%)  87 (9.7%) 
Yalcınkaya et al. [11]  167  -  334  137 (41%)  48 (14%)  53 (16%)  -  41(%12) 
Tastan et al. [29]  58  -  116  78 (67.2%)  18 (15.5%)  14 (12.0%)  - - 
Evliyaoglu et al. [30]  332  228  208  19 (18.3%)  9 (8.6%)  7 (6.7%)  32 (30.8%)  37 (35.6%) 
Tuzun et al. [31]  110  42  136  67 (49.2%)  13 (9.5%)  27 (19.8)%  4 (2.9%)  - 
Our studies  1.100  685 830  180  (21.6%)  81 (9.7%)  79 (9.5%)  159 (19.1%)  331 (39.8%) 4   The Open Rheumatology Journal, 2010, Volume 4  Ebru Etem 
Turkey is M694V (57.0 and 51.4%, respectively), followed 
by M680I (16.5 and 14.4%, respectively), and V726A (13.9 
and 8.6%, respectively). Evaluating other studies in Turkish 
population, carrier rates for four common MEFV gene 
mutations may appear to vary regionally (Table 2). Range of 
the frequencies of four common mutations in FMF patients 
were 15.6-67.2% for M694V, 1.5-14% for V726A, 1.5-
19.8% for M680I, for 3.2-30.8% for E148Q. Frequencies in 
our study were within the previously reported range. 
Possible explanations for the divergent frequencies of 
mutation rates in FMF patients may be population, 
geographical, environmental or genetic heterogeneities, 
patients’ inclusion criteria, methodological detection 
problems. In 12 population studies in Turkey, the mutations 
were genetically analyzed with many different techniques: 
sequencing, PCR-FLP, multiplex PCR, PCR-ELISA, reverse 
hybridization, ARMS, DGGE etc. [10, 11, 21-30]. 
  The M694V mutation was the most common one (21.8%) 
of the tested alleles in this cohort study (Table 3), as it was 
already reported in Turkish population and other populations 
[4, 9, 32-35]. The Turkish FMF study group demonstrated 
the close relationship between the M694V mutation and the 
severity of disease [31]. Some studies reported that the 
highest severity scores were observed in patients carrying the 
M694V mutation [11, 36]. Tunca et al. reported that patients 
with the M694V/M694V genotype were found to have an 
earlier age of onset and higher frequencies of arthritis and 
arthralgia compared with the other genotypes [37]. This 
study reveals an association between the earlier of the onset 
of the disease and the presence of mutation in codon 694 of 
exon 10. But, we did not detect any association between the 
other clinical characteristics, such as diseases severity, attack 
frequency etc. (Table 1) and the specific mutations or 
genotypes. 
  As E148Q is one of the common mutations in Turkish 
patients with FMF, the screening of E148Q mutation in a 
healthy Turkish cohort also allowed us to determine the 
E148Q mutation carrier rate in the Turkish healthy 
population. The carrier frequency of the E148Q mutation has 
been reported to be 12% in Turkish population, the present 
study we found 12%, the frequency in Ashkenazi Jews is 
10%, the frequency in Jews of Moroccan origin is 6.4%, and 
as high as 53% in Jews from the various ethnic groups [6, 9, 
10]. Several authors have considered E148Q as a mild 
mutation [38, 39]. Askentijevich et al. has been proposed 
that E148Q is a polymorphism, not a disease causing 
mutation, and has a low penetrance [39]. In accordance with 
this hypothesis, healthy individuals have been found to be 
homozygous for the E148Q variation [6, 9, 39]. Yilmaz et al. 
showed that the distribution of the E148Q MEFV mutation 
among healthy individuals (E148Q 12%) was significantly 
different (P < 0.005) from that found in patients (E148Q 
3.55%) [10]. They found 3.5% for E148Q carrier rate in 
patients group unlike our study. Tchernitchko et al. stated 
that the frequency of the E148Q allele was be similar in 
patients and healthy controls (3.62% and 3.75%, 
respectively, p = 0.93) [40]. Present study was showed that 
carrier frequencies were far higher among patients with FMF 
(19.1%) than among healthy carriers (12%). 11 of 36 E148Q 
compound heterozygotes (30.5%) were asymptomatic; the 
remaining patients had typical FMF attacks. Thus our results 
do not completely rule out the possibility that the E148Q 
mutation has an upregulating effect on inflammation in both 
FMF and other chronic inflammatory processes. We believe 
that symptomatic individuals who are E148Q carriers in 
patients group may be cosegregation with diseases causing 
unknown mutations in the east of Anatolia region. Thus, we 
planned a new study to detect of diseases causing unknown 
mutations by MEFV gene sequencing analysis in patients 
with E148Q compound heterozygotes and heterozygotes in 
our region. 
  It became evident that FMF is not fully recessive and 
some heterozygous patients tend to have relatively mild 
disease, but the disease cannot be distinguished clinically 
from that in homozygous patients [41]. Initially, some 
investigators assumed that these patients harbor less 
common MEFV mutations on the second allele in MEFV, but 
a number of investigators have failed to detect when 
complete sequencing of the gene was performed [38, 42, 43]. 
Our results are highly consistent with the existence of a 
clinical phenotype among some patients heterozygous for 
FMF and, thus, have several important implications. First, in 
some cases, FMF can be viewed as a dominant condition 
with low penetrance. A few reports of families with 
seemingly dominant inheritance have been published [44, 
45]. Second, these patients have other periodic fevers, such 
as TRAPS, HIDS, or cryopyrin-associated periodic 
syndromes (CAPS), cannot be completely excluded. A few 
recent reports have described patients who are compound 
heterozygotes for mutations in 2 known recurrent fever 
genes [46-48]. These patients were found to have 2 or more 
reduced penetrance mutations, such as E148Q in MEFV, 
R92Q or P46L in TNFRSF1A, V377I in MVK, and V198M 
in CIAS1. In some cases, patients presented with symptoms 
of both diseases or with a more severe disease, and their 
treatment was also compromised due to unknown gene 
interactions among mutations in the known recurrent fever 
genes [49]. Third, previous studies in FMF patients showed 
that the presence of modifying alleles in MICA and SAA are 
associated with a severe FMF phenotype and susceptibility 
to amyloidosis [4, 50]. Fourth, the proportion of patients 
with a single mutation varies between 16.5% and 33.8% [51, 
52]. The frequency of patients with one mutations in present 
study were 40.2%. Single-mutation FMF may be much more 
common than has previously been thought. The detection of 
a single mutation appears to be sufficient in the presence of 
clinical symptoms for the diagnosis of FMF and the 
initiation of a trial of colchicine. 
 Papodopoulos  et al. reported that the integrated 
knowledge of molecular genetics characterizing FMF in 
Turkey will facilitate the diagnosis and clinical decision 
especially in patients with atypical symptoms. For example, 
there are regions, such as the Aegean region, represented by 
Izmir, and territories where the majority of patients with 
FMF do not exhibit any MEFV mutations. This is totally the 
reverse in other cases, as Southeastern Turkey, where the 
presence of a MEFV mutation is obligatory to diagnose 
FMF. Turkish FMF patients are characterized by an 
increased genetic heterogeneity, explained by the 
intrapopulation differentiation [53]. Our patient group was 
more heterogeneous, because of the ethnic and cultural 
interactions in the east of Anatolia region of Turkey, than the 
patients group included the previous studies that were carried 
out in different regions of Turkey. It should be noted that the Familial Mediterranean Fever  The Open Rheumatology Journal, 2010, Volume 4   5 
FMF patients in our study had a broad spectrum of 
mutations, which may reflect the intercultural interactions of 
the ancient ethnic groups who lived in the east of Anatolia. 
Thus, the regional origin should be regarded as a 
determining factor in tailoring the diagnosis of FMF in 
Turkish patients. Previously reported studies showed the 
importance of the region of residence on disease severity 
[23]. The different results of studies which carried out in 
different regions but in similar ethnic groups show us that 
regional studies are as important as ethnic origin-based 
studies [53]. 
 Kelly  et al. emphasize that genetic  counseling is an 
educational
 process that seeks to assist affected and at-risk 
individuals
 to understand the nature of the genetic disorder, 
its transmission
  and the options open to them in the 
management of the disease
 and family planning [54]. Such 
knowledge
  can improve their understanding and eliminate 
wrong beliefs
  and conceptions about this disorder. 
Frequently, people have
 attributed their disease to the wrong 
cause, leading to unjustified
 guilt feelings [55]. It seems
 that 
close collaboration between the treating physician and
  the 
genetic counselor would be of great benefit and value to
 
FMF patients and their families.
  The intermarriage rate 
differs regionally in Turkey. For example, the incidence of 
intermarriage in the east of Anatolia region and The Aegean 
region in Turkey were as 33% and 1.4%, respectively [56, 
57]. Intermarriage between relatives may be increased the 
rate of diseases with autosomal recessive inheritance as 
FMF. Thus, we suggest that genetic counseling of FMF 
patients in Turkey should be different from other nations 
such as Turks, North African and Ashkenazi Jews, and 
Arabs because of the high incidence of intermarriage rate in 
the east of Anatolia. Firstly, we advise to get genetic testing 
done for the children and the spouses of such patients. 
Secondly, we recommend that all the intermarried couples 
with MEFV gene mutation carrier should be strongly 
monitor their future pregnancies by prenatal diagnosis to 
exclude the possibility of a homozygotes mutation carrier. 
  Our data imply that despite the heterogeneity, molecular 
diagnosis appear to be feasible in most patients, because a 
molecular diagnosis technique did not found MEFV gene 
mutation in only seven out of 415 patients. As we observed 
clinical heterogeneity and a high frequency of symptoms, 
our view is that symptomatic patients with heterozygote or 
negative patients with recurrent fevers and an increase in 
acute phase reactants during the attacks require colchicine 
treatment until as yet undetermined modifier genes or 
environmental factors are found, especially in the areas 
where the disease is prevalent. Those cases have to be 
detected as early as possible to arrange for treatment and 
adequate genetic counseling. 
  In conclusion, this study allowed us establishing the 
spectrum of the MEFV mutations among FMF patients in the 
east of Anatolia region of Turkey. The most important 
features were the predominance of the M694V mutation and 
the low frequency of non-mutated alleles. The molecular 
analysis of the MEFV gene is the only objective test that 
confirms the diagnosis in our cohort. A genotype-phenotype 
correlation showed a relationship between the M694V 
mutation and the earlier of onset of the disease. Many ethnic 
groups live in Anatolia and more ethnic origin-based studies 
are needed to determine the real effect of these mutations. 
Our study also confirms the mutational heterogeneity of 
FMF in Turkey. In addition, different intermarriage rates 
may be one reason for different mutation profiles in Turkey. 
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